The U.S. pharmaceutical company, the FDA, is expected to fully recognize Pfizer and Bioendech’s COVID-19 vaccine in September, the New York Times reported Tuesday.
Also read: Govt-19: Israel tightens health restrictions
According to the newspaper, citing well-known sources on the subject, the “unofficial date”, the Govt vaccine is expected to receive a full green light from the FDA “Labor Day (September 6) or earlier.”
Pfizer offers its vaccines under a provisional emergency authorization issued on December 11, 2020.
Last week, the FDA said in a statement that the Kovit vaccine accreditation process was “one of the agency’s top priorities” and expects it to deliver its decision before the deadline.
Full serum approval may boost confidence and induce more Americans to be vaccinated at a time when the high epidemic delta virus is raising the number of cases in the country.
192 million Americans have received at least one dose of the vaccine, or 58% of the population or 70% of adults.
At the same time, as of July 27, according to the Centers for Disease Control and Prevention (CDC), the number of Covid-19 cases has risen to 66,000 a day, six times more than in June.
The other widely used vaccine, Moderna, which was approved under the emergency regime, was also used, but later, applied for full approval.
The newspaper reported that Johnson & Johnson and its single-dose vaccine have not yet been requested.